FutureChem Receives FDA IND Approval for Phase 1 Clinical Trial of Prostate Cancer Diagnostic Radiopharmaceutical
[Asia Economy Reporter Eunmo Koo] FutureChem, a company specializing in the development of new radiopharmaceutical drugs, announced on the 3rd that it has received approval from the U.S. Food and Drug Administration (FDA) for the Phase 1 clinical trial Investigational New Drug (IND) application of Prostaview (FC303), a radiopharmaceutical for prostate cancer diagnosis. Accordingly, FutureChem plans to begin clinical trials to verify the safety and efficacy of the new drug, centered around Johns Hopkins University Hospital in the United States.
Currently, in the U.S., expectations for PSMA (Prostate-Specific Membrane Antigen) mechanism-based prostate cancer diagnostic radiopharmaceuticals are rising due to the Phase 3 clinical trial of 'F18-DCFPyl' by Progenics, a Nasdaq-listed company.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
A FutureChem official stated, "According to our preclinical results, Prostaview binds more specifically to PSMA-positive tumors than existing drugs and has a lower absorption rate in normal organs," adding, "It will provide clearer and more accurate disease imaging, overwhelming market leaders."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
